

Arg-Gly-Asp-Cys TFA Biochemical | Arg-Gly-Asp-Cys biochemical

Arg-Gly-Asp-Cys TFA

CATALOG #
AAA228191


PRODUCT SYNONYMS

Arg-Gly-Asp-Cys TFA; Arg-Gly-Asp-Cys biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2171504-22-4
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	Arg-Gly-Asp-Cys-functionalized chitosan (0.25-1 mg/mL; 2-7 days) favors cell growth and an increase in cellular proliferation compared to the control cells (viability 140%)[1]. Arg-Gly-Asp-Cys-functionalizes chitosan derivatives exhibit in vitro wound healing properties by enhancing fibroblast proliferation and adhesion[1].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
MRTX849 analog 24, CAS 2490716-96-4



Structure
MRTX849 analog 24, CAS 2490716-96-4

ADDITIONAL INFORMATION

Related Product Information for Arg-Gly-Asp-Cys biochemical	Arg-Gly-Asp-Cys TFA is the binding motif of fibronectin to cell adhesion molecules. Arg-Gly-Asp-Cys TFA can inhibit platelet aggregation and fibrinogen binding.
References	1. Jay B Fell, et al. Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS G12C Inhibitor for the Treatment of Cancer. J Med Chem. 2020 Jul 9;63(13):6679-6693.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.